Brief: Brii Biosciences Updates On Strategic Clinical Development Progress
27/12/2022 16:33
Dec 27 (Reuters) - Brii Biosciences Ltd 2137.HK :
* BRII BIOSCIENCES PROVIDES UPDATE ON STRATEGIC CLINICAL
DEVELOPMENT PROGRESS
* BRII BIOSCIENCES LTD - INITIATION OF PHASE 2 POSTPARTUM
DEPRESSION (PPD) STUDY PLANNED FOR EARLY 2023 TO ADVANCE
POTENTIAL FIRST-OF-ITS-KIND TREATMENT
* BRII BIOSCIENCES LTD - TOPLINE PHASE 2 DATA FROM MULTIPLE
HEPATITIS B VIRAL (HBV) INFECTION FUNCTIONAL CURE COMBINATION
STUDIES EXPECTED IN FIRST HALF OF 2023
* BRII BIOSCIENCES LTD - INITIATION OF PHASE 2 POSTPARTUM
DEPRESSION (PPD) STUDY PLANNED FOR EARLY 2023 TO ADVANCE
POTENTIAL FIRST-OF-ITS-KIND TREATMENT
* BRII BIOSCIENCES- U.S. FDA LIFTED CLINICAL HOLD ON
BRII-732
ALLOWING CO TO REINITIATE A CLINICAL TRIAL TO INVESTIGATE A
LOWER ONCE-WEEKLY ORAL DOSE
Source text for Eikon: ID:nPn60K1Jva
Further company coverage: 2137.HK
Recent news on Brii Biosciences
See all newsBrief: BRII Biosciences Discloses Launch Of BRISC, An SIRNA Therapeutics Discovery Platform
China's Brii Biosciences interim net loss narrows on lower R&D expenses
Brief: Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million
Brief: Brii Biosciences Says Arbitration Between Brii And Vir Remains In Early Stages With No Resolution
Brief: Brii Biosciences Submits Demand For Arbitration Against VIR